Mesoblast Rises on Plan to Buy Stem-Cell Business: Sydney Mover – Bloomberg
|
Mesoblast Rises on Plan to Buy Stem–Cell Business: Sydney Mover
Bloomberg Mesoblast Ltd. (MSB) climbed the most in eight months in Sydney trading after agreeing to buy a stem–cell business of Osiris Therapeutics Inc. (OSIR) for as much as $100 million to gain new treatments. The maker of stem–cell therapies rose as much as … |
